Liver cancer
Conditions
Interventions
Liver cancer resection cohort and liver cancer ablation cohort:None
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Primary liver cancer was confirmed through pathological biopsy (surgical resection specimens, puncture biopsy specimens) or comprehensive clinical diagnosis (combined with abdominal enhanced CT/MRI, serum alpha-fetoprotein (AFP) and other imaging and serological indicators), strictly meeting the diagnostic criteria in the "Diagnosis and Treatment Guidelines for Primary Liver Cancer (2026 Edition)" Exclude other types of liver cancer such as intrahepatic cholangiocarcinoma and mixed cell carcinoma; 2. Received simple liver cancer resection (including partial hepatectomy, lobectomy, segectomy, etc., excluding liver transplantation) or simple local ablation treatment (including radiofrequency ablation, microwave ablation, excluding other ablation methods such as cryoablation and anhydrous ethanol injection), and the operation/ablation process went smoothly There were no serious complications during the operation (such as massive hemorrhage, fatal arrhythmia, etc.) that led to the termination of the surgery/ablation. The patient was smoothly transferred to a general ward or intensive care unit for continued treatment after the operation. 3. The clinical data is complete, and the following information can be fully obtained: General clinical data, laboratory test results at different time points before and after surgery, preoperative and postoperative imaging data, pathological sections and reports (required for patients with liver cancer resection and those with biopsy after ablation), immunohistochemical/fluorescence test results (for those with tests), molecular index test results (for those with tests), serology-related test results Moreover, long-term postoperative follow-up (with a follow-up period of no less than 5 years) can be completed through outpatient follow-up, telephone follow-up and other methods to obtain complete outcome information. 4. Age >=18 years old, gender not limited, no upper age limit (excluding those who cannot tolerate treatment due to vital organ failure caused by advanced age, as clearly stated in the exclusion criteria); 5. No history of other malignant tumors (including previous history of malignant tumors and concurrent malignant tumors in other parts), and no severe failure of vital organs such as the heart, lungs, kidneys, and brain (such as heart failure, respiratory failure, renal insufficiency, and uremia)
Exclusion criteria
Exclusion criteria: 1. Secondary liver cancer (such as gastric cancer, colorectal cancer, lung cancer and other tumors that have metastasized to the liver), or combined with non-primary hepatocellular carcinoma types such as intrahepatic cholangiocarcinoma and mixed cell carcinoma; Diseases that may affect the occurrence of postoperative complications and tumor recurrence, such as concurrent malignant tumors, severe organ dysfunction (heart, lung, kidney, brain, etc.), coagulation disorders, severe infections (such as sepsis), autoimmune diseases, etc. 2. The clinical data is incomplete and key indicators are missing, including but not limited to: no clear pathological diagnosis results, no preoperative core laboratory test indicators (such as liver function, tumor markers), no postoperative follow-up data, no imaging examination reports, etc., making it impossible to complete the data entry and analysis of the research. In the short term (within 30 days after the operation), death due to non-liver cancer-related causes (such as severe cardiovascular and cerebrovascular events, accidents, severe infections, etc.) cannot be evaluated for postoperative complications and tumor recurrence. 3. Refusal to follow up or loss to follow-up during the follow-up process (less than 3 follow-ups, the last follow-up time is less than 6 months from the surgery/ablation time, and subsequent information cannot be obtained through channels such as phone calls, family members, and community hospitals), and complete postoperative outcome information cannot be obtained; The patient or their family members refused to provide the relevant information required for the research or did not cooperate with the follow-up work, making it impossible to complete the data collection and subsequent analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time of early recurrence;Postoperative complications;Neoplasm recurrence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of complications;Overall survival (OS); | — |
Countries
China
Contacts
Public ContactHan Shaoshan
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed